Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations

Indian Pediatrics

Volumn 51, Issue 3, 2014, Pages 191-197

  Mukherjee, Aparna ^a   Singla, Mohit ^a   Velpandian, T ^a   Sirohiwal, Anju ^a   Vajpayee, M ^a   Singh, Ravinder ^a   Kabra, S K ^a   Lodha, Rakesh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antiretroviral; Child; India; Serum levels

Indexed keywords

GENERIC DRUG; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILDHOOD DISEASE; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; STEADY STATE; TERTIARY HEALTH CARE; TREATMENT OUTCOME; VIRUS LOAD; ADOLESCENT; BLOOD; CHILD; FEMALE; HIV INFECTIONS; HUMAN; INFANT; MALE; PRESCHOOL CHILD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUGS, GENERIC; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MALE; NEVIRAPINE; STAVUDINE;

EID: 84898658063     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-014-0382-3     Document Type: Article

References (27)

1. World Health Organization, UNAIDS, UNICEF. Global HIV/AIDS Response, Epidemic update and health sector progress towards Universal Acces 2011. Available from: http://www.who.int/hiv/pub/progress-report2011/hiv-full-report- 2011.pdf. Accessed December 21, 2013.
2. World Health Organization. Preferred Antiretroviral Medicines for Treating and Preventing HIV Infection in Younger Children 2008. Available from: http://www.who.int/hiv/pub/paediatric/antiretroviral/en/index.html. Accessed December 21, 2013.
3. L'homme RFA, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS. 2008;22:557-565.
4. Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, et al. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets. AIDS. 2012;26:1795-1800.
5. National AIDS Control Organization. National Paediatric ART Dosing Schedules Desk Reference 2010. Available from: http://naco.gov.in/upload/ Care%20&%20TreatmentNational-Paediatric-ART-Dosing-Schedules-Desk-Reference- Jan-2010.pdf. Accessed:December 21, 2013.
6. World Health Organization. WHO Case Definitions of HIV for Surveillance and Revised Clinical staging and Immunological Classification of HIV-related Disease in Adults and Children. 2006. Available from: http://www.who.int/hiv/ pub/guidelines/hivstaging/en/index.html. Accessed December 21, 2013.
7. Agent summary statement for human immunodeficiency viruses (HIVs) including HTLV-III, LAV, HIV-1, and HIV-2. MMWR. 1988;37:1-17.
8. Mistri HN, Jangid AG, Pudage A, Gomes N, Sanyal M, Shrivastav P. High throughput LC-MS/MS method for simultaneous quantification of lamivudine, stavudine and nevirapine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853:320-332.
9. Gehrig AK, Mikus G, Haefeli WE, Burhenne J. Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. Rapid Commun Mass Spectrom. 2007;21:2704-2716.
10. Bartlett JG. The DHHS adult ART guidelines are revised. Hopkins HIV Rep 2005;17:6-7.
11. Brantley RK, Williams KR, Silva TMJ, Sistrom M, Thielman NM, Ward H, et al. AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Braz J Infect Dis. 2003;7:16-22.
12. Balikuddembe R, Kayiwa J, Musoke D, Ntale M, Baveewo S, Waako P, et al. Plasma drug level validates self-reported adherence but predicts limited specificity for nonadherence to antiretroviral therapy. ISRN Pharmacol. 2012;2012:274978.
13. Minzi O, Mugoyela V, Gustafsson L. Correlation between lamivudine plasma concentrations and patient selfreported adherence to antiretroviral treatment in experienced HIV patients. Ther Clin Risk Manag. 2011;7:441-446.
14. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Geneva: WHO; 2010. Available from: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html. Accessed December 21, 2013.
15. Ellis JC, L'homme RFA, Ewings FM, Mulenga V, Bell F, Chileshe R, et al. Nevirapine concentrations in HIVinfected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther. 2007;12:253-260.
16. Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker S, et al. Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J Antimicrob Chemother. 2009;64:1251-1259.
17. Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, et al. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J. 2010;29:940-944.
18. Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS. 2005;19:1495-1499.
19. Hemanth Kumar AK, Ramachandran G, Rajasekaran S, Padmapriyadarsini C, Narendran G, Anitha S, et al. Pharmacokinetics of lamivudine and stavudine in generic fixed-dose combinations in HIV-1 infected adults in India. Indian J Med Res. 2009;130:451-457.
20. L'homme RFA, Dijkema T, Warris A, van der Ven AJAM, Gibb DM, Burger DM. Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. J Antimicrob Chemother. 2007;59:92-96.
21. Byakika-Tusiime J, Chinn LW, Oyugi JH, Obua C, Bangsberg DR, Kroetz DL. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One. 2008;3:e3981.
22. Poerksen G, Pollock L, Moons P, Chesshyre E, Burger D, Khoo S, et al. Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. Antivir Ther. 2010;15:343-350.
23. Narang VS, Lulla A, Malhotra G, Purandare S. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects. J Clin Pharmacol. 2005;45:265-274.
24. Ramachandran G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, Anitha S, et al. Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India. J Int Assoc Physicians AIDS Care. 2007;6:251-254.
25. Monif T, Rao Thudi N, Koundinya Tippabhotla S, Khuroo A, Marwah A, Kumar Shrivastav V, et al. A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers. Clin Ther. 2007;29:2677-2684.
26. Swaminathan S, Ramachandran G, Agibothu Kupparam HK, Mahalingam V, Soundararajan L, Perumal Kannabiran B, et al. Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. J Antimicrob Chemother. 2011;66:1354-1359.
27. Burger D, Ewings F, Kabamba D, L'homme R, Mulenga V, Kankasa C, et al. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. Ther Drug Monit. 2010;32:369-372.